Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EIK1001 |
Synonyms | |
Therapy Description |
EIK1001 is a TLR 7/8 agonist, which potentially induces inflammatory responses and activation of immune cells, leading to antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 2521). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EIK1001 | BDB-001|BDB 001|EIK-1001|EIK 1001|BDB001 | TLR7 Agonist 12 TLR8 Agonist 9 | EIK1001 is a TLR 7/8 agonist, which potentially induces inflammatory responses and activation of immune cells, leading to antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 2521). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03486301 | Phase I | EIK1001 EIK1001 + Pembrolizumab | Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab | Active, not recruiting | USA | 0 |
NCT04819373 | Phase II | EIK1001 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Completed | USA | 0 |